{
}
Barclays has lowered its price target for Crispr Therapeutics (CRSP) from $56 to $42 while maintaining an Equal Weight rating, following positive early results from the CTX310 Phase 1 clinical trial. Analysts project an average target price of $80.22, indicating a potential upside of 121.96% from the current price of $36.14. However, GuruFocus estimates a fair value of $27.30, suggesting a downside of 24.46%.
CRISPR Therapeutics AG (CRSP) closed at $38.36, down 1.26%, underperforming the S&P 500's 0.12% gain. The company faces a projected EPS of -$1.20 and a revenue forecast of $10.83 million, reflecting significant declines from the previous year. Currently holding a Zacks Rank of #3 (Hold), CRISPR's stock has dropped 12.18% over the past month, contrasting with the Medical sector's 2.25% loss.
Darwin Wealth Management LLC and Elkhorn Partners Limited Partnership recently acquired new positions in CRISPR Therapeutics, with investments of approximately $43,000 and $54,000, respectively. Hedge funds and institutional investors own 69.20% of the stock, which has a "Hold" rating among analysts, with a consensus price target of $78.38. CEO Samarth Kulkarni sold 15,000 shares for $826,500, reducing his ownership by 7.63%.
Crispr Therapeutics AG (CRSP) shows a buy signal near $32.79 with a target of $40.06 and a stop loss at $32.70. Conversely, a short position is advised near $40.06, targeting $32.79 with a stop loss at $40.18. For swing and day trading, buy slightly over $40.06 with targets of $42.18 and appropriate stop losses.
CRISPR technology is transforming genetic research and applications, with the global market projected to grow from USD 3.2 billion in 2023 to USD 15.0 billion by 2033, at a CAGR of 16.7%. North America leads in market share, driven by advancements in healthcare and agriculture, while ethical and regulatory challenges persist. The technology enhances crop resilience and supports biomedical research, paving the way for innovative therapies and sustainable agricultural practices.
Wall Street analysts are optimistic about CRISPR Therapeutics, projecting potential gains of 114% to 152% by 2025, driven by its gene therapy Casgevy and promising trial results for CTX112, a treatment for blood cancers. However, slow sales of Casgevy and significant operational losses raise concerns about the company's financial stability. Investors should weigh the high risks against potential rewards before committing funds.
Wall Street analysts are optimistic about CRISPR Therapeutics, projecting potential gains of 114% to 152% in 2025, driven by its gene therapy, Casgevy, which recently received FDA approval for treating sickle cell disease and beta-thalassemia. However, despite the promising technology, the company faces challenges in generating sales and manufacturing personalized treatments. Analysts have adjusted price targets, with one lowering it to $85 while maintaining a buy rating, and another setting a target of $100.
Geode Capital Management LLC increased its stake in CRISPR Therapeutics, now holding over 1 million shares valued at $47.4 million. Institutional investors own 69.20% of the stock, while CRISPR's recent performance includes a new 52-week low of $36.70. Analysts maintain a "Hold" rating, with an average price target of $78.38.
A grant is set to advance CRISPR-based gene therapy targeting neurological disorders, with the global market projected to grow from USD 4.14 billion in 2023 to USD 18.84 billion by 2034, driven by rising demand for gene therapy and advancements in technology. The biomedical research segment leads in revenue, while North America is expected to dominate market share, with Asia Pacific showing the fastest growth. Notable collaborations, such as Vertex Pharmaceuticals and CRISPR Therapeutics, highlight the transformative potential of CRISPR in treating genetic conditions.
CRISPR Therapeutics AG's stock has fallen to a 52-week low of $38.2, reflecting a 38.23% decline over the past year amid investor concerns about regulatory challenges and clinical trial progress. Despite a strong balance sheet with more cash than debt, analysts have mixed views, with targets ranging from $30 to $268. The company is advancing its gene editing pipeline, including the launch of CASGEVY® and ongoing trials for CTX112™ and CTX131™, while planning to appoint Briggs Morrison, M.D., to its Board of Directors.
CRISPR Therapeutics AG
Companies
| Symbol | CRSP |
| Name | CRISPR Therapeutics AG |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | Switzerland |
| State | |
| City | Zug |
| Zipcode | 6300 |
| Website | http://www.crisprtx.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
crispr therapeutics price target lowered by barclays amid clinical trial results
12:18 09.05.2025
crispr therapeutics stock declines as earnings report approaches
00:00 15.01.2025
crisper therapeutics attracts institutional investment amid mixed analyst ratings
14:25 14.01.2025
Crispr Therapeutics trading strategies and market signals for January 2025
13:20 14.01.2025
CRISPR technology market poised for rapid growth and transformative advancements
Euro
United States Dollar
Editas Medicine, Inc.
CRISPR Therapeutics AG
Intellia Therapeutics, Inc.
USA
Show more
13:04 14.01.2025
analysts predict significant gains for crisper therapeutics amid challenges ahead
10:34 14.01.2025
biotech stock poised for significant gains amid challenges in treatment sales
10:34 14.01.2025
crisper therapeutics faces challenges as stock hits new 12 month low
19:59 13.01.2025
advancements in crisper technology drive growth in gene editing market
United States Dollar
Vertex Pharmaceuticals Incorporated
Editas Medicine, Inc.
CRISPR Therapeutics AG
GBR
USA
Show more
17:45 13.01.2025
CRISPR Therapeutics stock falls to 52-week low amid biotech market challenges
16:09 13.01.2025
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Industry Trends
AI Innovations
Retail and Consumer Goods
Emerging Startups
Funding Rounds & Investments
Venture Capital Investments
Fintech Startups
AI Applications
Stock Market Updates
Economic Indicators
Government Economic Policies
Global Trade Developments
Financial Scams and Security
Consumer Protection Regulations
Cryptocurrency Trends
AI Ethics & Policy
Energy Sector Developments
Industry Mergers & Acquisitions
Countries:
Companies:
Alphabet Inc.
Google Inc.
Google LLC
Nvidia Corporation
Battery Ventures X LP
Khosla Ventures LLC
Poalim Equity Ltd.
Oxyzo Financial Services Ltd.
BOCHK Asset Management Ltd.
HSBC Saudi Arabia
Marvell Technology Inc.
Nippon Steel Corporation
Sony Corporation
Ford Motor Company
Mitsubishi Motors Corporation
Eternal Capital LP
Maximus International Ltd.
Ather Energy Ltd.
Ola Electric Mobility B.V.
Super Micro Computer Inc.
Currencies:
United States Dollar
Indian Rupee
Offshore Chinese Yuan
Chinese Yuan
Hong Kong Dollar
Egyptian Pound
Saudi Riyal
Indonesian Rupiah
People: